<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610046</url>
  </required_header>
  <id_info>
    <org_study_id>METC 22-057</org_study_id>
    <nct_id>NCT05610046</nct_id>
  </id_info>
  <brief_title>The Impact of Passive Heat Treatment on Glycaemic Response During an Oral Glucose Tolerance Test in Diabetic Patients</brief_title>
  <acronym>Sauna-OGTT</acronym>
  <official_title>The Impact of Passive Heat Treatment on Glycaemic Response During an Oral Glucose Tolerance Test in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is a metabolic disease with a rapidly increasing incidence&#xD;
      world-wide. The disease is characterizedby a decreased glucose tolerance as a result of&#xD;
      insulin resistance, resulting in poor blood glycaemic control. Blood glucose&#xD;
      loweringmedications are widely available, but their effect stagnates as T2DM progresses. New&#xD;
      treatment regimens are required to combatthe disease. Although therapies such as physical&#xD;
      exercise have been shown to induce beneficial effects on glycaemic control inT2DM patients,&#xD;
      not all patients are able to perform exercise. Passive heating treatment (PHT) might be an&#xD;
      alternative strategy toreduce insulin resistance, as it has been postulated to have&#xD;
      comparable effects on the cardiovascular system as exercise. PHT hasbeen linked to numerous&#xD;
      health benefits, including improved cardiovascular- and pulmonary function, pain alleviation&#xD;
      and metabolichealth. In addition, long term use of PHT shows promising effects on glycaemic&#xD;
      control in T2DM patients. However, the acute effectsof PHT on glucoregulation are yet to be&#xD;
      determined. Therefore, in this study we will assess the acute impact of passive heat&#xD;
      treatment on the post-prandial glycaemic response during an OGTT in T2DM patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 26, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Actual">April 14, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover, randomized, controlled trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>In this trial, neither the participants, nor the researchers who perform the trial days will be blinded to the intervention allocation. However, the researchers performing the blood analysis are blinded to the treatment allocation and are not involved in the research study during the trial days.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Glycaemic response (Matsuda index)</measure>
    <time_frame>120 minutes</time_frame>
    <description>OGTT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>Baseline</time_frame>
    <description>fasting glucose and insulin values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma volume/hematocrit</measure>
    <time_frame>Throughout test day (3h)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gutt insulin sensitivity index</measure>
    <time_frame>120 minutes</time_frame>
    <description>from OGTT values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Non-heated sauna session</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The test days will consist of sitting in an infrared sauna cabin (HM-LSE-3 Professional edition, Health Mate, Belgium). Participants will sit in an infrared sauna at 21° Celsius for a total of 40 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heated sauna session</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The test days will consist of sitting in an infrared sauna cabin (HM-LSE-3 Professional edition, Health Mate, Belgium). Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Infrared sauna heating</intervention_name>
    <description>Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.</description>
    <arm_group_label>Heated sauna session</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham sauna</intervention_name>
    <description>Participants will sit in an inactive infrared sauna at room temperature (21° Celsius) for a total of 40 minutes.</description>
    <arm_group_label>Non-heated sauna session</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥50 years old&#xD;
&#xD;
          -  Body mass index 18.5 - 35 kg/m2&#xD;
&#xD;
          -  DM type 2&#xD;
&#xD;
          -  Using oral blood glucose lowering medication&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insulin dependence&#xD;
&#xD;
          -  Changes in diabetes medication in the past 3 months&#xD;
&#xD;
          -  Allergy for one of the food items used&#xD;
&#xD;
          -  &gt;5% weight change in the previous 6 months&#xD;
&#xD;
          -  Participating in a structured (progressive) exercise program, or in the past 3 months.&#xD;
&#xD;
          -  Frequent (once per week or more) user of infrared (or traditional) sauna in the past 3&#xD;
             months&#xD;
&#xD;
          -  Inability to tolerate sauna/high temperatures&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Diagnosed with cardiovascular disease (e.g. unstable angina pectoris or recent&#xD;
             myocardial infarction), kidney failure (eGFR &lt; 60 ml/min/1.73m2), rheumatoid arthritis&#xD;
&#xD;
          -  Diagnosed musculoskeletal, GI tract, metabolic (except diabetes) or pulmonary (e.g.&#xD;
             COPD) disorders that are expected to influence study outcomes&#xD;
&#xD;
          -  Having a pacemaker, defibrillator, or any other type of metal implant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc JC van Loon, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Centre +</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 2, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2022</study_first_posted>
  <last_update_submitted>May 3, 2023</last_update_submitted>
  <last_update_submitted_qc>May 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

